Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex

Neuro-Oncology

Volumn 17, Issue 12, 2015, Pages 1550-1559

  MacKeigan, Jeffrey P ^a   Krueger, Darcy A ^b  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Everolimus; Mammalian target of rapamycin; Sirolimus; Tuberous sclerosis complex

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUBERIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADVANCED CANCER; ANGIOMYOLIPOMA; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; GENE; GENE DELETION; GENE IDENTIFICATION; GENE INSERTION; GENE MUTATION; GRAFT REJECTION; HEMANGIOFIBROMA; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; MEDICAL DECISION MAKING; METABOLIC DISORDER; MOUTH ULCER; MYCOSIS; NEUROENDOCRINE TUMOR; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; SEIZURE; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; GLIOMA, SUBEPENDYMAL; MALE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; EVEROLIMUS; FEMALE; GLIOMA, SUBEPENDYMAL; HUMANS; MALE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84958544667     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov152     Document Type: Article

References (99)

1. Gomez MR. Varieties of expression of tuberous sclerosis. Neurofibromatosis. 1988;1(5-6):330-338.
2. Bissler JJ, Kingswood JC. Renal angiomyolipomata. Kidney Int. 2004;66(3):924-934.
3. Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243-254.
4. Bolton PF, Park RJ, Higgins JN, et al. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain. 2002;125(Pt 6):1247-1255.
5. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: a review of neurological aspects. Eur J Paediatr Neurol. 2002;6(1):15-23.
6. Novartis Pharmaceuticals Corporation. Afinitor (everolimus tablets for oral administration). Afinitor Disperz (everolimus tablets for oral suspension) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014.
7. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angio-myolipoma in tuberous sclerosis complex or lymphangioleio-myomatosis. N Engl J Med. 2008;358(2):140-151.
8. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364(17):1595-1606.
9. Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One. 2011;6(9):e23379.
10. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleio-myomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071-4081.
11. Koenig MK, Hebert AA, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12(3):121-126.
12. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305-1315.
13. Povey S, Burley MW, Attwood J, et al. Two loci for tuberous sclerosis: one on 9q34 and one on 16p13. Ann Hum Genet. 1994;58(Pt 2):107-127.
14. Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet. 1994;6(2):193-196.
15. Henske EP, Scheithauer BW, Short MP, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet. 1996;59(2):400-406.
16. Sepp T, Yates JR, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet. 1996;33(11):962-964.
17. Jansen FE, Braams O, Vincken KL, et al. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurol. 2008;70(12):908-915.
18. Nellist M, van den Heuvel D, Schluep D, et al. Missense mutations to the TSC1 gene cause tuberous sclerosis complex. Eur J Hum Genet. 2009;17(3):319-328.
19. Hoogeveen-Westerveld M, Wentink M, van den Heuvel D, et al. Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with tuberous sclerosis complex. Hum Mutat. 2011;3(4):424-435.
20. Nellist M, Sancak O, Goedbloed MA, et al. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur J Hum Genet. 2005;13(1):59-68.
21. Sancak O, Nellist M, Goedbloed M, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype:phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet. 2005;13(6): 731-741.
22. Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64-80.
23. Aicher LD, Campbell JS, Yeung RS. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis. J Biol Chem. 2001;276(24):21017-21021.
24. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009;37(Pt 1): 217-222.
25. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412(2): 179-190.
26. Li Y, Inoki K, Guan KL. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol Cell Biol. 2004;24(18): 7965-7975.
27. Raju GP, Urion DK, Sahin M. Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol. 2007;36(2):128-131.
28. Kotulska K, Borkowska J, Mandera M, et al. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. Childs Nerv Syst. 2014;30(12):2037-2042.
29. Kwiatkowski DJ, Wittemore V, Theile E. Pathogenesis of TSC in the brain. In: Crino PB, Mehta R, Vinters HV, eds. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-Blackwell; 2010:159-185.
30. Lopes MBS, Wiestler OD, Stemmer-Rachamimov AO, Sharma MC. Tuberous sclerosis complex and subependymal giant cell astrocytoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC Press; 2007:218-221.
31. Barrows BD, Rutkowski MJ, Gultekin SH, et al. Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma. Turk Patoloji Derg. 2012; 28(2):95-103.
32. Buccoliero AM, Franchi A, Castiglione F, et al. Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathol. 2009;29(1):25-30.
33. Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49:255-265.
34. Cuccia V, Zuccaro G, Sosa F, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst. 2003;19(4):232-243.
35. de Ribaupierre S, Dorfmuller G, Bulteau C, et al. Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery. 2007;60(1): 83-89.
36. Berhouma M. Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatrics. 2010;6(2):103-110.
37. Levine NB, Collins J, Franz DN, Crone KR. Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim Invasive Neurosurg. 2006;49(5):317-320.
38. Sun P, Kohrman M, Liu J, et al. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin. 2012;28(4):657-663.
39. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10): 721-726.
40. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28(10):727-732.
41. Baker H, Sidorowicz A, Sehgal SN, Vézina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo). 1978;31(6):539-545.
42. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977;55(1):48-51.
43. Houchens DP, Ovejera AA, Riblet SM, Slagel DE. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol. 1983;19(6):799-805.
44. Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc. 1990;22(4):1638-1641.
45. Dilling MB, Dias P, Shapiro DN, et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54(4):903-907.
46. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996;56(17):3895-3897.
47. Clackson T, Metcalf C, Rivera V, et al. Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol. 2003;22. Abstract 882.
48. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22(5):909-918.
49. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004;64(1):252-261.
50. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22(12): 2336-2347.
51. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008;26(10):1588-1595.
52. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253(5022):905-909.
53. Van Duyne GD, Standaert RF, Karplus PA, et al. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. J Mol Biol. 1993;229(1):105-124.
54. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273(5272):239-242.
55. Yang H, Rudge DG, Koos JD, et al. mTOR kinase structure, mechanism and regulation. Nature. 2013;497(7448):217-223.
56. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356(9225):194-202.
57. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplant. 2001;71(2):271-280.
58. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281.
59. Tedesco SH, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10(6): 1401-1413.
60. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
61. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256-4265.
62. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
63. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26(3): 361-367.
64. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801-1811.
65. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861): 125-132.
66. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381:817-824.
67. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharma-cokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83-95.
68. Wyeth Pharmaceuticals Inc. Rapamune (sirolimus) oral solution and tablets [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2012.
69. Rauktys A, Lee N, Lee L, Dabora SL. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatology. 2008;8:1.
70. Jacobsen W, Serkova N, Hausen B, et al. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001;33(1-2):514-515.
71. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40(8):573-585.
72. Klawitter J, Gottschalk S, Hainz C, et al. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. 2010;23(3):608-619.
73. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006; 59(3):490-498.
74. Mutizwa MM, Berk DR, Anadkat MJ. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1)) in two patients with tuberous sclerosis. Br J Dermatol. 2011;165(4):922-923.
75. Wheless JW, Almoazen H. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. J Child Neurol. 2013;28(7):933-936.
76. Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis-associated facial angiofibroma. J Eur Acad Dermatol Venereol. 2012;26(10):1315-1318.
77. Lam C, Bouffet E, Tabori U, et al. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors. Pediatric Blood Cancer. 2010;54(3):476-479.
78. Cardamone M, Flanagan D, Mowat D, et al. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 2014;17:631-638.
79. Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 2008;23(10):1238-1239.
80. Krueger DA, Care MM, Agricola K, et al. Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma. Neurol. 2013;80:574-580.
81. Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014;15(13):1513-1520.
82. Kotulska K, Chmielewski D, Borkowska J, et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17(5):479-485.
83. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679-687.
84. Soefje SA, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Targeted Oncol. 2011;6(2):125-129.
85. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev. 2014;28(3):126-133.
86. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplant. 1997;64(1):36-42.
87. Yoon S, Ung N, Mehta N, et al. Medical management with mTOR inhibitors vs surgical resection: comparison of clinical outcomes for subependymal giant cell astrocytomas (SEGA) in tuberous sclerosis complex. Neurol. 2013;80. (Meeting abstracts 1): PL01.001.
88. Yu J, Parkhitko A, Henske EP. Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM. Autophagy. 2011;7(11): 1400-1401.
89. McBride KL, Varga EA, Pastore MT, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Research. 2010;3(3):137-141.
90. Gustafson S, Zbuk KM, Scacheri C, Eng C. Cowden syndrome. Semin Oncol. 2007;34(5):428-434.
91. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95(1):29-39.
92. Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res. 2008;68(17):7066-7072.
93. Zhou J, Blundell J, Ogawa S, et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci. 2009;29(6):1773-1783.
94. Iacobas I, Burrows PE, Adams DM, et al. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer. 2011;57(2):321-323.
95. Schmid GL, Kassner F, Uhlig HH, et al. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatr Res. 2014;75(4):527-534.
96. Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018-1024.
97. Pfizer. Torisel Kit (temsirolimus) injection, for intravenous infusion only [package insert]. Philadelphia, PA: Pfizer; May 2012.
98. Mita MM, Poplin E, Britten CD, et al. Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol. 2013;24(4):1104-1111.
99. European Medicines Agency. Withdrawal assessment report for Jenzyl. December 3, 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Application-withdrawal-assessment- report/human/002259/WC500138917.pdf. Accessed May 21, 2015.